PMA device
SURGIFLO Hemostatic Matrix Kit with Thrombin
Ferrosan Meidcal Devices A/S · Agent, Absorbable Hemostatic, Collagen Based (LMF, Class III) · First FDA decision May 16, 2016, newest Jul 9, 2025Surgical bleeding and hemostasis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
5
Naming "SURGIFLO"
MAUDE reports
211
Brand "SURGIFLO", since 2015
PubMed studies
83
Mentioning "SURGIFLO"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SURGIFLO Hemostatic Matrix Kit with Thrombin
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- SURGIFLO Hemostatic Matrix Kit with ThrombinPMA supplement
P990004-S073 · Decided Jul 9, 2025 · 90 days after receipt · Normal 180 Day Track
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
P990004-S067 · Decided Dec 30, 2024 · 241 days after receipt · Normal 180 Day Track
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- SURGIFLO HEMOSTATIC MATRIX KIT WITH THROMBINPMA supplement
P990004-S025 · Decided May 16, 2016 · 570 days after receipt · Normal 180 Day Track
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "SURGIFLO", any status and sponsor, newest update first.
- Absorbable Hemostatic Fluid Gelatin TrialPivotal-lookingNot yet recruiting
Medprin Regenerative Medical Technologies Co., Ltd.Not on our public-company list
NCT07830797 · 324 participants (planned) · Start Sep 8, 2026 · Primary completion Sep 8, 2026
Device: Absorbable Hemostatic Fluid Gelatin; Absorbable Hemostatic Fluid Gelatin SURGIFLO Haemostatic Matrix · For: Surgical Bleeding
- The Affect of Hemostasis Technique During Laparoscopic Ovarian Cystectomy on Future FertilityPivotal-lookingCompleted
Rambam Health Care CampusAcademic, hospital or other
NCT03109964 · 127 participants · Start Nov 20, 2018 · Primary completion Mar 31, 2021
Device: Bipolar coagulation forceps (ETHICON inc.); SURGIFLO hemostatic matrix (ETHICON inc.) · For: Cyst Ovary
Sites: Haifa, Israel
CryoLife EuropaPublic (AORT)
NCT02835391 · 90 participants · Start Nov 2015 · Primary completion Jul 2017
Device: PerClot; Floseal, Surgicel, Surgiflo, Arista · For: Endometriosis; Ovarian Cyst; Menorrhagia and 2 more
Sites: Barcelona, Spain
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SURGIFLO", and for the whole product code for context.
This brand
211 reports: 13 malfunction, 194 injury, 3 death
Whole product code LMF
1,445 reports: 207 malfunction, 1,171 injury, 61 death
Newest reports for this brand
3008478369-2026-00040 · Received Oct 26, 2026
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Off-Label Use
Patient problem as coded: Unspecified Nervous System Problem
3008478369-2026-00039 · Received Oct 26, 2026
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Off-Label Use
Patient problem as coded: Unspecified Nervous System Problem
3008478369-2026-00038 · Received Oct 21, 2026
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Embolism/Embolus
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- SURGIFOAM" Absorbable Gelatin Powder Kit, Product Code 1979.Open, Classified
Z-1881-2024 · Started Apr 23, 2024 · Posted by FDA May 22, 2024
Reason given: Some applicator tips from these lots had open seals.
Cause as FDA categorized it: Under Investigation by firm · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Mckesson Medical-Surgical Inc. Corporate Office
Z-1584-2022 · Started May 25, 2022 · Posted by FDA Aug 26, 2022
Reason given: Facility Temperature excursions (from June 2021-August 2021) prior to delivery; exposure to higher temperatures may have impacted product effectiveness. All lots received between 06/01/21-9/30/21.
Cause as FDA categorized it: Environmental control · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Z-0292-2013 · Started Aug 21, 2012 · Posted by FDA Nov 16, 2012
Reason given: SURGIFLO Hemostatic Matrix Kit & SURGIFLO Hemostatic Matrix Kit with Thrombin have an issue within the packing process where a cut could potentially breach the double Tyvek pouch of the packaging.
Cause as FDA categorized it: Packaging · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
2 more recall records with a free account
Published research
The most relevant PubMed records for "SURGIFLO"[tiab]. The summary above synthesizes these.
- Real-world economic and clinical outcomes associated with current hemostatic matrix use in spinal surgery.
Danker W, Kelkar SS, Marston XL, et al. · J Comp Eff Res · 2022Research Support, Non-U.S. Gov't
- FLOSEAL Versus SURGIFLO in Lumbar Surgery: Similar Outcomes, Different Costs in a Matched Cohort Analysis.
Ye IB, Thomson AE, Smith RA, et al. · World Neurosurg · 2023
- Surgiflo® may have a potential impact on the healing process in cricotracheal resection anastomosis.
El-Fattah AMA, Ebada HA, Tawfik A · Clin Otolaryngol · 2020Randomized Controlled Trial
- Gelatin-Based Hemostatic Agents: Histopathologic Differences.
Wolkow N, Jakobiec FA, Yoon MK · Ophthalmic Plast Reconstr Surg · 2018Research Support, Non-U.S. Gov't
- Revision cricotracheal resection: our experience.
Ebada HA, El-Fattah AMA, Tawfik A · J Laryngol Otol · 2021
- Utilization of SURGIFLO® Hemostatic Matrix Reduces Intraoperative Blood Loss During Posterior Instrumented Thoracolumbar Spinal Surgery for Patients With Adult Spinal Deformity.
Takahashi H, Funayama T, Noguchi H, et al. · Cureus · 2025
- In Situ Attached Photothermal Immunomodulation-Enhanced Nanozyme for the Inhibition of Postoperative Malignant Glioma Recurrence.
Nie D, Ling Y, Lv W, et al. · ACS Nano · 2023Research Support, Non-U.S. Gov't
- Cost-consequence analysis of two different active flowable hemostatic matrices in spine surgery patients.
Makhija D, Rock M, Ikeme S, et al. · J Med Econ · 2017
- Real-World Clinical and Economic Outcomes Associated with Surgiflo® vs Floseal in Cardiovascular Surgeries in the US.
Danker W, Aggarwal J, Kelkar SS, et al. · Clinicoecon Outcomes Res · 2022
- Hemostatic efficacy of two topical adjunctive hemostats in a porcine spleen biopsy punch model of moderate bleeding.
MacDonald MH, Zhang G, Tasse L, et al. · J Mater Sci Mater Med · 2021Evaluation Study
- Efficacy and safety assessment of gelatin hemostatic matrix in a burr hole neurosurgical beagle model.
Ma J, Gan S, Shu R, et al. · Sci Rep · 2025Research Support, Non-U.S. Gov't
- Similar patient outcomes yet different hospital costs between flowable hemostatic agents.
David G, Lim S, Gunnarsson C, et al. · J Med Econ · 2015Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LMF.
- SURGIFOAM® Absorbable Gelatin SpongeFerrosan Meidcal Devices A/S · PMA 2026
- Floseal Hemostatic MatrixBaxter Healthcare Corp · PMA 2015
- Vitagel Surgical HemostatStryker Corp. · PMA 2013
- Helistat Absorbable Collagen Hemostatic Sponge/OraFOAM Absorbable Collagen Hemostatic SpongeIntegra LifeSciences Corporation · PMA 2019
- Instat Collagen Absorbable HemostatETHICON, Inc. · PMA 2007
- Avitene Flowable Collagen HemostatDavol Inc., Sub. C. R. Bard, Inc. · PMA 2025
- Collastat Absorbable Collagen Hemostatic AgentsIntegra LifeSciences Corporation · PMA 2009
- Floseal (R) Matrix Hemostatic Sealant and Proceed (Tm) Hemostatic SealantBaxter Healthcare Corp · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.